Axcelis科技设计公司 ACLS 深 沪
已收盘 12-19 16:00:00 美东时间
82.72
+1.590
+1.96%
华盛通- 最 高83.99
- 今 开80.97
- 成交量 87.56万股
- 最 低 80.97
- 昨 收 81.13
- 总市值 26.58亿
- 52周最高 102.93
- 市盈率 静 13.46
- 换手率 2.73%
- 52周最低 40.40
- 委 比 73.00%
- 总股本 3212.95万
- 历史最高 201.00
- 量 比 1.47
- 振 幅 3.72%
- 历史最低 2.844
- 每 手 1
- 风险率 13.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of broader chip stocks are trading higher in possible sympathy with NVIDIA, which rose on reports suggesting the US is launching a review of advanced NVIDIA AI chip sales to China. The sector may also be continuing to gain following strong guidance from Micron.
Shares of broader chip stocks are trading higher in possible sympathy with NVID...
12-19 23:53
Axcelis to Showcase Advanced Ion Implant Solutions at SEMICON Japan 2025
BEVERLY, Mass., Dec. 10, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced t...
12-10 21:00
Shares of companies in the broader chip sector are trading lower, reversing following an earlier NVIDIA-driven rally.
Shares of companies in the broader chip sector are trading lower, reversing fol...
11-21 01:17
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
B. Riley Securities Maintains Neutral on Axcelis Technologies, Lowers Price Target to $84
B. Riley Securities analyst Craig Ellis maintains Axcelis Technologies (NASDAQ:ACLS) with a Neutral and lowers the price target from $85 to $84.
11-06 01:12
Axcelis Technologies Sees Q4 Adj EPS $1.12 vs $0.96 Est; Sees Sales $215.000M vs $199.754M Est
Axcelis Technologies (NASDAQ:ACLS) is looking for Q4 Adj EPS of $1.12 vs $0.96 analyst estimate. sees sales of $215.000 million vs $199.754 million analyst estimate.
11-04 20:03
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion, Inc. reported strong financials, market adoption, and clinical trial progress in its Q3 2025 update. The company has a debt-free balance sheet with $13.3 million in cash, supporting commercial growth. Nociscan scan volumes increased 89% year-over-year, marking three consecutive quarters of record utilization across U.S., U.K., and E.U. markets. The CLARITY pivotal trial is advancing on schedule with early 3-month readouts expected in Q2...
10-14 10:09
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
